Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.

ABSTRACT:

SUBMITTER: Gao L 

PROVIDER: S-EPMC9937662 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature